Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
about
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibDevelopment of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.
P2860
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Investigational therapies up t ...... tial anti-cancer therapeutics.
@en
type
label
Investigational therapies up t ...... tial anti-cancer therapeutics.
@en
prefLabel
Investigational therapies up t ...... tial anti-cancer therapeutics.
@en
P2093
P2860
P50
P1476
Investigational therapies up t ...... ntial anti-cancer therapeutics
@en
P2093
Anatole Cessot
Audrey Thomas-Schoemann
Benoit Blanchet
Francois Goldwasser
Jean-Marie Tigaud
Jean-Philippe Durand
Jennifer Arrondeau
Jerome Alexandre
Pascaline Boudou-Rouquette
P2860
P304
P356
10.1517/13543784.2015.1005736
P407
P577
2015-01-20T00:00:00Z